1.317 Billion USD
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Investors Business Daily 16:45 06/12/2022
Is Novavax Stock A Buy On Its Massive Sales Beat Despite Unexpected Losses?
Is Novavax stock a buy after the Covid vaccine maker handily bea...
The Motley Fool 05:21 06/12/2022
3 Supercharged Growth Stocks With 393% to 1,153% Upside in 2023, According to Wall Street
Select Wall Street analysts believe these fast-growing companies...
Zacks Investment Research 12:02 30/11/2022
Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL
The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX)...
Zacks Investment Research 13:32 28/11/2022
Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why
Novavax (NVAX) drops to record lows as the delayed product launc...